Sign in Create account

Caplin Point Laboratories Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: CAPLIPOINT BSE: 524742
₹2716.40
▼ -27.60 (-1.01%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
72/100
Strong
Valuation
20/100
Expensive
Momentum
50/100
Neutral

QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹20,648 Cr
PE (TTM)
47.9
Industry median 36.1 (152 companies)
Price to Book
5.7
PEG (TTM)
2.2
Institutions holding %
8.24%
FII + DII, latest filed period
Piotroski Score
3
Relative return vs Nifty50, qtr %
13.4
Relative return vs Sector, qtr %
5.9
Free Cash Flow
₹275 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
40.18%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
18.96%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
1.25%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
40.16%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
11.16%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
6.70
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
2429.73
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
59.32%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
74.23%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
70.45%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
16.06%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
21.96%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
17.89%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 3)
  • Yes Debt to equity is below 0.5 (0.00)
  • Yes Return on equity is 15% or more (17.9%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.0%
Low 2663.3000 · High 2797.8000
1W return
-2.8%
Low 2663.3000 · High 2990.0000
1M return
7.9%
Low 2490.5000 · High 2990.0000
52W return
32.0%
Low 1500.3000 · High 2990.0000
Lifetime High ₹2867.4000 (Sept. 24, 2026)
Lifetime Low ₹178.2000 (June 24, 2014)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
2768.9
10D
2764.4
20D
2731.8
50D
2634.7
100D
2469.5
200D
2112.7

Delivery and volume

Day avg. delivery
43.7%
Week avg. delivery
36.3%
Month avg. delivery
23.5%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

2725.83
Pivot
First resistance2788.37
Second resistance2860.33
Third resistance2922.87
First support2653.87
Second support2591.33
Third support2519.37
Day RSI50.5
Day MFI67.2
Day MACD46.15
Day MACD signal49.47

Beta

1M1.30
3M0.74
1Y0.85
3Y1.01

Price change analysis

↑ 7.9%
Over 1 Month
LowHigh
2490.502990.00
↑ 5.9%
Over 3 Months
LowHigh
2382.502990.00
↑ 73.0%
Over 6 Months
LowHigh
1508.002990.00
↑ 32.0%
Over 1 Year
LowHigh
1500.302990.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 47.9 (own history: 28.8–58.8)
Fair Value Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹203 Cr
Net profit (June 30, 2026)
₹120 Cr
Basic EPS (June 30, 2026)
₹15.8400

Ranks #28 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter70.57%
  • Mutual funds2.03%
  • FII/FPI5.75%
  • Other DII0.46%
  • Public21.19%

Largest holders

NameCategoryShares %Shares
P VIJAYALAKSHMIPromoter24.7100%18778790
PAARTHIPAN C CPromoter18.6400%14167192
ASHOK GORKEY PARTHEEBANPromoter11.9100%9050000
PARTHEEBAN VIVEK SIDDARTHPromoter11.8500%9009371
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRSPublic2.8700%2178485

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 70.57% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 6.15% to 5.75% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 2.02% to 2.03% in Jun 2026 qtr

3 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 63 insider trades, 4 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
24 Mar 2023 P Vijayalakshmi Promoter group Buy 0 ₹0
24 Nov 2021 Arulsudar Natrajan Employee / designated person Sell 0 ₹0
24 Nov 2021 Arulsudar Natrajan Employee / designated person Sell 0 ₹0
24 Nov 2021 Satish Krishnan Employee / designated person Sell 0 ₹0
19 Nov 2021 Subramanian Narayanaswamy Employee / designated person Sell 0 ₹0
19 Nov 2021 Subramanian Narayanaswamy Employee / designated person Sell 0 ₹0
19 Nov 2021 Arulsudar Natrajan Employee / designated person Sell 0 ₹0
8 Nov 2021 Venkatachalam P Employee / designated person Buy 0 ₹0
8 Nov 2021 Vamsee Krishna Tata Employee / designated person Buy 0 ₹0
8 Nov 2021 Umesh Shetty Employee / designated person Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 10 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
26 Aug 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 396,355 1901.2800 NSE
26 Aug 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 396,355 1899.6000 NSE
19 Aug 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 444,478 1761.7200 NSE
19 Aug 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 444,478 1763.5800 NSE
9 Sep 2021 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 381,306 908.1900 NSE
9 Sep 2021 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 381,306 908.5400 NSE
27 Jul 2021 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 414,981 957.6200 NSE
27 Jul 2021 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 414,981 957.3700 NSE
26 Jul 2021 XTX MARKETS LLP Bulk Buy 464,203 908.9100 NSE
26 Jul 2021 XTX MARKETS LLP Bulk Sell 460,816 910.5800 NSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 4.0000 — —

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
12 Aug 2026 Financial Results/Dividend Yes
14 May 2026 Financial Results/Dividend Yes
5 Feb 2026 Financial Results Yes
5 Nov 2025 Financial Results Yes
7 Aug 2025 Financial Results/Dividend Yes

Corporate Announcements

All 5 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
28 Sep 2026 Insider Trading / SAST Caplin Point Laboratories Ltd - 524742 - Closure of Trading Window
25 Sep 2026 AGM/EGM Caplin Point Laboratories Ltd - 524742 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
25 Sep 2026 Company Update Caplin Point Laboratories Ltd - 524742 - Clarification With Respect To Volume Movement
25 Sep 2026 AGM/EGM Caplin Point Laboratories Ltd - 524742 - Shareholder Meeting / Postal Ballot-Outcome of AGM
25 Sep 2026 Company Update Caplin Point Laboratories Ltd - 524742 - Clarification sought from Caplin Point Laboratories Ltd

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (59.3%)
  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (2429.7x)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

  • PE above 35 (47.9) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Part of: NIFTY 500, NIFTY 500

Frequently asked questions about Caplin Point Laboratories Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.